Discover personalized clinical trial options designed to support your journey, safely, confidentially, and at no cost.
Takes less than 2 minutes • 100% confidential
Epilepsy is a neurological disorder marked by recurrent, unprovoked seizures caused by abnormal elec…
Recurrent seizures, Temporary confusion, Staring spells and more.
Genetic mutations affecting ion channels or neurotransmitter receptors; Structural brain abnormalities (tumors, stroke, head injury).
Anti-Seizure Medications (ASMs), Ketogenic Diet and more.
Symptoms
Common Symptoms
Quality of Life Impact
Epilepsy significantly impacts daily life, driving restrictions, employment challenges, social stigma, and anxiety around seizure unpredictability are common. With good seizure control, most people lead full, active lives.
With the right care and support, most people live full, active lives.
Causes & Risk Factors
Health Insights
Active Global Trials
39+
Across all phases
Symptom Frequency
78%
Patients report primary symptom
Trial Improvement Rate
68%
Report improvement within 3 months
Avg. Trial Duration
14 mo
Median length of participation
Symptom Frequency Among Patients
Treatment
First-line treatment, levetiracetam, lamotrigine, valproate, lacosamide and 20+ others.
High-fat, low-carbohydrate diet particularly effective in drug-resistant pediatric epilepsy.
Implantable device that reduces seizure frequency by stimulating the vagus nerve.
Brain-implanted device that detects and responds to abnormal electrical activity.
Resection of the seizure focus for suitable drug-resistant candidates, seizure-free in ~60%.
FDA-approved CBD medication for Dravet syndrome and Lennox-Gastaut syndrome.
Clinical Trials
UCB Pharma
Testing whether CBD added to existing seizure medications reduces seizure frequency in adults with drug-resistant focal epilepsy.
NCT05812341
Daily Life
You are not alone. Millions of people navigate this condition every day, and with the right support system and treatments, a meaningful life is absolutely within reach.
Community Support
Connect with thousands of patients and caregivers
Digital Tools
Track symptoms and share insights with your care team
Specialist Network
Access to leading neurologists and researchers
Education Hub
Evidence-based resources tailored to your journey
Why Join a Trial
Try innovative therapies before they're widely available, some with breakthrough potential.
Receive close monitoring and support from leading specialists throughout the trial.
Study-related care, tests, and the investigational treatment are provided at no charge.
Research Pipeline
Current pipeline overview for Epilepsy
Pipeline data is indicative. Source: ClinicalTrials.gov & WHO ICTRP.
Patient Stories
“After years of failed medications, HEKMA matched me with a Phase III trial in 48 hours. I'm now 6 months seizure-free.”
Ahmed K.
✓ 6 months seizure-free“After years of failed medications, HEKMA matched me with a Phase III trial in 48 hours. I'm now 6 months seizure-free.”
Ahmed K.
✓ 6 months seizure-freePublished with patient consent. Details may be anonymised.
News
FDA Approves New Anti-Seizure Medication for Treatment-Resistant Focal Epilepsy
The FDA has approved cenobamate (Xcopri) expanded indication for adults with focal onset impaired awareness seizures that have not responded to at least two prior anti-seizure medications.
FDA · Mar 18, 2025
FAQ
Resources
